| __timestamp | CymaBay Therapeutics, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 21226345 |
| Thursday, January 1, 2015 | 17026000 | 87718074 |
| Friday, January 1, 2016 | 15941000 | 93831530 |
| Sunday, January 1, 2017 | 18938000 | 79419009 |
| Monday, January 1, 2018 | 58124000 | 132166913 |
| Tuesday, January 1, 2019 | 83837000 | 89124838 |
| Wednesday, January 1, 2020 | 35882000 | 65782137 |
| Friday, January 1, 2021 | 64542000 | 88845513 |
| Saturday, January 1, 2022 | 67995000 | 134715000 |
| Sunday, January 1, 2023 | 80118000 | 180142000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and CymaBay Therapeutics, Inc. have demonstrated varying levels of investment in R&D, reflecting their strategic priorities.
From 2014 to 2023, Intra-Cellular Therapies consistently outspent CymaBay, with an average R&D expenditure nearly double that of its competitor. Notably, in 2023, Intra-Cellular Therapies allocated approximately 180% more to R&D than CymaBay, highlighting its aggressive pursuit of innovation.
This trend underscores the importance of R&D in driving growth and maintaining a competitive edge in the biotech sector. As these companies continue to evolve, their R&D investments will likely play a pivotal role in shaping their future trajectories and the broader industry landscape.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds